Notwithstanding encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from managed care entities. These insurers are frequently erecting obstacles to access, such as steep price requirements and prior authorization that hinder consumer opportunity. Ma